Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.38 |
| ▸ | CNR1 | P21554 | 6/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 7/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2645445 | 1.00 | CNR2 (0.38) | CNR2CNR1DDR1EPHX2TAS1R3 | |
| SCHEMBL2646527 | 0.89 | AKR1C3 (0.36) | CNR2CNR1DDR1EPHX2TAS1R3 | |
| SCHEMBL2646524 | 0.89 | AKR1C3 (0.36) | CNR2CNR1DDR1EPHX2TAS1R3 | |
| SCHEMBL2645675 | 0.83 | CNR2 (0.39) | CNR2CNR1EPHX2TAS1R3TAS1R1 | |
| SCHEMBL2645681 | 0.83 | CNR2 (0.39) | CNR2CNR1EPHX2TAS1R3TAS1R1 | |
| SCHEMBL2645877 | 0.83 | CNR2 (0.39) | CNR2CNR1EPHX2TAS1R3TAS1R1 | |
| SCHEMBL2645874 | 0.83 | CNR2 (0.39) | CNR2CNR1EPHX2TAS1R3TAS1R1 | |
| SCHEMBL2646037 | 0.80 | KCNH2 (0.50) | EPHX2 | |
| SCHEMBL2646038 | 0.80 | KCNH2 (0.50) | EPHX2 | |
| SCHEMBL2646052 | 0.79 | KMT2A (0.47) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242397-B1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| EP-1242397-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| US-6353111-B1 | WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A | HOFFMANN-LA ROCHE INC. | 2002-03-05 | — | — | US | disclosed |
| WO-2001044216-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-21 | — | — | WO | disclosed |